Strategic acquisition strengthens leadership position in direct sales and gut and microbiome health marketSALT LAKE CITY, Oct. 02, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the closing of its previously announced acquisition of LoveBiome, a pioneering direct sales company dedicated to comprehensive microbiome care and wellness solutions. Under the term ...

Group 1 - LifeVantage Corporation will participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025, with CEO Steve Fife and CFO Carl Aure presenting [1][2] - The presentation is scheduled for approximately 11:00 a.m. Eastern Time and will be available via a live webcast on the company's Investor Relations website [2] - LifeVantage specializes in nutrigenomics, offering products that activate health processes at the cellular level, including the Protandim® family, TrueScience® Liquid Collagen, and various health-supporting nutrients [3] Group 2 - LifeVantage was founded in 2003 and is headquartered in Lehi, Utah, focusing on health and wellness products that work with individual biology [3] - The company also provides a business opportunity for independent consultants to sell its products and promote entrepreneurship [3]

Core Insights - LifeVantage Corporation reported a strong financial performance for the fourth quarter and full fiscal year 2025, with a revenue growth of approximately 13% to $55.1 million in Q4 and 14.2% to $228.5 million for the full year [6][9][14] - The international business showed growth for the first time in nearly three years, particularly in the Asia/Pacific and Europe regions, which increased by approximately 8% [6][9] - The company has a strong balance sheet with $20.2 million in cash and no debt, positioning it well for future growth [22] Fourth Quarter Fiscal 2025 Summary - Revenue for Q4 was $55.1 million, a 12.6% increase year-over-year, with a 14.1% increase in the Americas and a 7.6% increase in Asia/Pacific & Europe [7][9] - Gross profit was $44.0 million, representing 79.9% of revenue, compared to 79.5% in Q4 fiscal 2024 [8] - Net income for Q4 was $2.0 million, or $0.15 per diluted share, up from $1.3 million, or $0.10 per diluted share in the prior year [12][9] Fiscal Year 2025 Summary - Total revenue for fiscal 2025 was $228.5 million, a 14.2% increase from $200.2 million in fiscal 2024 [14] - Gross profit for the year was $183.7 million, or 80.4% of revenue, compared to 79.3% in fiscal 2024 [15] - Net income for the year was $9.8 million, or $0.75 per diluted share, compared to $2.9 million, or $0.23 per diluted share in fiscal 2024 [19] Share Repurchase and Dividend - The company repurchased 0.3 million shares for $3.1 million during fiscal 2025, with approximately $17.3 million remaining under the current repurchase program [21] - A cash dividend of $0.045 per common share was declared, to be paid on September 16, 2025 [23] Fiscal Year 2026 Guidance - LifeVantage expects revenue in the range of $225 million to $240 million for fiscal 2026, with adjusted EBITDA of $23 million to $26 million [24]

Core Insights - LifeVantage Corporation will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York [1] - The company's President and CEO, Steve Fife, along with CFO Carl Aure, will present to investors on September 10, 2025, at approximately 1:00 p.m. Eastern Time [2] Company Overview - LifeVantage Corporation is a pioneer in nutrigenomics, focusing on how nutrition and natural compounds can activate health at the cellular level [3] - The company offers a range of scientifically validated products, including the Protandim® family, TrueScience® Liquid Collagen, and the MindBody GLP-1 System™, among others [3] - LifeVantage was founded in 2003 and is headquartered in Lehi, Utah, with a business model that includes independent consultants selling products and sharing business opportunities [3]

Core Insights - LifeVantage Corporation will release its financial results for the fourth quarter and full fiscal year ended June 30, 2025, on September 4, 2025, after market close [1] - A conference call for investors will take place on the same day at 2:30 p.m. Mountain Time [1] Financial Results Announcement - The financial results will cover the fourth quarter and the full fiscal year ending June 30, 2025 [1] - The announcement will be made after the stock market closes on September 4, 2025 [1] Conference Call Details - Investors can participate in the live call by dialing (877) 704-4453 from the U.S. or (201) 389-0920 for international callers [2] - A telephone replay will be available approximately two hours after the call and will last until September 18, 2025 [2] Webcast Information - A live webcast of the conference call will be available on the Investor Relations section of the company's website [3] - The webcast will be archived for approximately 30 days [3] Company Overview - LifeVantage Corporation is a pioneer in nutrigenomics, focusing on how nutrition and natural compounds can enhance health at the cellular level [4] - The company offers a range of products, including the Protandim® family, TrueScience® Liquid Collagen, and various health-supporting nutrients [4] - LifeVantage was founded in 2003 and is headquartered in Lehi, Utah [4]

Core Insights - LifeVantage Corporation is set to launch its products in Iceland in September 2025, marking a significant step in its international expansion strategy [1][4] - The launch will feature a selection of top-performing products and three curated wellness stacks tailored to various health goals, with plans for additional products in the future [2][4] - The introduction of the LifeVantage business opportunity in Iceland will be supported by the Evolve Compensation Plan, allowing consultants to enroll for the launch [3][4] Company Overview - LifeVantage Corporation specializes in nutrigenomics, focusing on how nutrition and natural compounds can enhance health at the cellular level [6] - The company's product line includes scientifically validated activators such as Protandim®, TrueScience® Liquid Collagen, and the MindBody GLP-1 System™, among others [6][7] - LifeVantage operates through independent consultants who sell products and promote business opportunities to aspiring entrepreneurs [6] Leadership Perspective - Steve Fife, President and CEO, expressed excitement about the Iceland launch, emphasizing its role in empowering individuals with health tools and supporting their entrepreneurial journeys [4]

Core Insights - LifeVantage Corporation announced new results from its second human clinical study on the MindBody GLP-1 System™, showing significant improvements in GLP-1 levels and related health outcomes [1][2] Clinical Study Results - The average increase in GLP-1 production improved to over 200%, up from a previously reported 140% [2] - Participants experienced an average weight loss of 11 pounds within 12 weeks, with some losing up to 25 pounds [6] - There was a reported decrease in total body fat percentage of up to 9% and a decrease in visceral fat of up to 24% [6] - Participants reported a 100% weight loss from fat, not muscle, and a 6% increase in skeletal muscle [6] Behavioral Changes - 95% of participants reported decreased sugar cravings, while 89% reported decreased fast-food cravings [6] - 85% of participants indicated they now eat for health instead of emotions, and 81% reported an increased ability to resist snacking [6] - 89% of participants ate less at meals, and 86% reported feeling less hungry [6] Company Background - LifeVantage Corporation is a pioneer in nutrigenomics, focusing on how nutrition and natural compounds can enhance health [5] - The company offers a range of products, including the MindBody GLP-1 System™, aimed at promoting optimal health at the cellular level [5]

Core Insights - LifeVantage Corporation held its global Activate 2025 virtual event on July 12, 2025, focusing on Consultant engagement and growth while celebrating innovation in the direct selling model [1][4] Group 1: Campaigns and Initiatives - The company launched the "Summer in the Fast Lane" campaign, which builds on the previous "Drive" message, aimed at motivating Consultants to take control of their success and offering various sales incentives [2][5] - The "Summer in the Fast Lane" campaign includes the new High Speed Health Stack, featuring products like MindBody GLP-1 System™, Protandim® Nrf2 Synergizer®, and a free Protandim® NAD Synergizer®, promoting weight management and long-term wellness [3][5] - This campaign is part of a new quarterly business cadence designed to drive growth through focused sales sprints and community support among Consultants [5] Group 2: Events and Training - The Global Activate 2025 event included training sessions and discussions with top Consultants, and announced the next U.S. Momentum Academy scheduled for October 23-25 in Dallas, TX, featuring in-person training and networking opportunities [4][5] Group 3: Company Overview - LifeVantage Corporation is a pioneer in nutrigenomics, offering a range of health products designed to activate optimal health processes at the cellular level, including the Protandim® family and other activation-supporting nutrients [6]

Company Overview - LifeVantage operates in the wellness industry, focusing on nutrigenomics and direct selling of supplements, energy, and skin-care products [8, 12, 14] - The company's product subscriptions account for 70% of monthly revenue, indicating a stable, recurring order base [46] - LifeVantage has approximately 52,000 independent consultants sharing its products every month [56] - The company operates in 6 of the top 10 direct selling markets globally [60] Financial Performance - In fiscal year 2023, LifeVantage reported revenue of $213.4 million and adjusted EBITDA of $11.7 million [6] - As of January 31, 2024, the company's market capitalization was $68.3 million and enterprise value was $51.0 million [6] - Cash at December 31, 2023, was $17.3 million, and the company is debt-free [6] - For the second quarter of fiscal year 2024, net revenue was $51.624 million, a 3.8% decrease year-over-year [146] Strategic Initiatives - The company is focused on increasing active monthly purchasers, enrolling new business builders and customers, and retaining them longer through the LV360 growth strategy [77] - LifeVantage offers a quarterly dividend of $0.035 per common share and declared a special dividend of $0.40 per share paid in September 2023 [137] - The company has a stock repurchase program with $24.2 million remaining under the current authorization [137]

Core Viewpoint - LifeVantage Corporation reported strong financial results for the third fiscal quarter of 2025, with a significant increase in revenue and profitability, driven by robust demand for its products and international expansion efforts [4][5]. Financial Performance - Revenue for the third quarter ended March 31, 2025, was $58.4 million, representing a 21.1% increase year-over-year. Excluding foreign currency fluctuations, revenue increased by 22.1% [5][9]. - Gross profit for the quarter was $47.3 million, or 81.0% of revenue, compared to 78.9% in the same period of fiscal 2024, attributed to a favorable product sales mix and reduced inventory costs [6]. - Adjusted EBITDA rose by 27% to $6.4 million from $5.1 million a year ago [9][12]. - Net income for the quarter was $3.5 million, or $0.26 per diluted share, compared to $1.7 million, or $0.13 per diluted share, in the prior year [11][9]. Regional Performance - Revenue in the Americas increased by 29.5%, with a notable 31.4% rise in the United States. Conversely, revenue in the Asia/Pacific & Europe region decreased by 7.2%, with a constant currency decline of approximately 4.7% [5][9]. Operational Highlights - The company launched its Evolve Compensation Plan in several Asian markets and introduced the MindBody GLP-1 System™ in multiple international regions, indicating a strategic focus on global market expansion [4]. - Active Independent Consultants increased by 6.1% to 52,000, with a 12.9% rise in the Americas, while the Asia/Pacific & Europe region saw a decline of 5.6% [32]. Balance Sheet and Liquidity - Cash and cash equivalents as of March 31, 2025, were $22.5 million, up from $16.9 million at the end of June 2024, with no debt outstanding [13]. - The company generated $10.8 million in cash from operations during the first nine months of fiscal 2025, compared to $9.6 million in the same period of fiscal 2024 [13]. Shareholder Returns - LifeVantage declared a cash dividend of $0.045 per common share, scheduled for payment on June 13, 2025 [15]. Fiscal Year Guidance - The company expects revenue for fiscal year 2025 to be in the range of $228 million to $235 million, with adjusted EBITDA guidance of $21 million to $24 million and adjusted earnings per share between $0.72 and $0.88 [16].